WO2017160548A1 - Compositions et méthodes de traitement de la presbytie - Google Patents

Compositions et méthodes de traitement de la presbytie Download PDF

Info

Publication number
WO2017160548A1
WO2017160548A1 PCT/US2017/021244 US2017021244W WO2017160548A1 WO 2017160548 A1 WO2017160548 A1 WO 2017160548A1 US 2017021244 W US2017021244 W US 2017021244W WO 2017160548 A1 WO2017160548 A1 WO 2017160548A1
Authority
WO
WIPO (PCT)
Prior art keywords
concentration
aceclidine
tropicamide
composition
ophthalmological
Prior art date
Application number
PCT/US2017/021244
Other languages
English (en)
Inventor
Gerald Horn
Lee NORDAN
Original Assignee
Presbyopia Therapies, LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US15/073,139 external-priority patent/US9833441B2/en
Priority claimed from US15/073,089 external-priority patent/US9844537B2/en
Priority claimed from US15/235,431 external-priority patent/US10052313B2/en
Application filed by Presbyopia Therapies, LLC filed Critical Presbyopia Therapies, LLC
Priority to CA3017755A priority Critical patent/CA3017755A1/fr
Priority to MX2018011300A priority patent/MX2018011300A/es
Priority to EP17767172.4A priority patent/EP3429584A4/fr
Priority to CN201780017733.8A priority patent/CN108883102A/zh
Priority to JP2018548865A priority patent/JP2019508472A/ja
Publication of WO2017160548A1 publication Critical patent/WO2017160548A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4174—Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4409—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 4, e.g. isoniazid, iproniazid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia

Definitions

  • Excellent unaided distance vision is also known as emmetropia.
  • the inability to focus on distant focal points is known as myopia and the inability to focus on near focal points is known as hyperopia.
  • "distance" vision is considered any focal point 1 meter or more from the eye and near vision is any focal point less than 1 meter from the eye.
  • the minimum focal length at which an object will come into focus is known as the "near point”.
  • Accommodation The change in focus from distance to the near point and any focal point in between is called accommodation.
  • Presbyopia occurs because as a person ages the eye's accommodative ability which uses near reflex-pupil constriction, convergence of the eyes and particularly ciliary muscle contraction, decreases. This reduction in accommodation results in an inadequate change in the normal thickening and increased curvature of the anterior surface of the lens that is necessary for the shift in focus from distant objects to near objects.
  • Important near focus tasks affected by presbyopia include viewing computer screens (21 inches) and reading print (16 inches).
  • Presbyopia is a normal and inevitable effect of ageing and is the first unmistakable sign for many in their forties that they are getting older.
  • Presbyopia carries with it a stigma resulting from the limitation in ability to quickly function at many tasks requiring focusing at both distant and near points, which once occurred almost immediately.
  • these tasks can be performed only by the use of eyeglasses, contact lenses or after undergoing invasive surgery.
  • One such optical modification, the monovision procedure can be executed with the use of glasses, contact lenses or even surgery.
  • the monovision procedure corrects one eye for near focus and the other eye for distance focus.
  • monovision correction is normally accompanied by loss of depth perception and distance vision particularly in dim light (e.g. night).
  • AcuFocus work by inlaying a pinhole on the cornea to increase the depth of focus.
  • a similar effect can be achieved with general miotic agents, such as pilocarpine (a nonselective muscarinic acetylcholine receptor agonist), carbachol (a non-selective muscarinic acetylcholine receptor agonist), and phospholine iodide (an acetylcholinesterase inhibitor).
  • These general miotics can induce a pinhole pupil at sufficient concentrations to achieve pupils below 2.0 mm and potentially extend depth of focus much like an inlay, but at concentrations sufficient to cause pinhole pupil diamters of 2.0 mm or less these agents trigger increased ciliary muscle contraction and induce accommodation of any remaining reserves, improving near vision at the expense of distance vision in individuals who still retain some accommodative function.
  • Miotic agents have been described in various patent and patent applications for the treatment of presbyopia.
  • US Patent Nos. 6,291,466 and 6,410,544 describe the use of pilocarpine to regulate the contraction of ciliary muscles to restore the eye to its resting state and potentially restore its accommodative abilities.
  • WO/2013/041967 describes the use of pilocarpine with oxymetazoline or meloxicam to temporarily overcome ocular conditions such as presbyopia.
  • US Patent No. 8,299,079 (HEK Development LLC) describes the use of direct acting general miotic agents such as pilocarpine, carbachol and phospholine iodide with the alpha 2 selective vasoconstrictor brimonidine at a concentration from 0.05% to 3.0% w/v.
  • brimonidine concentrations of about 0.20% (or any at or above 0.05%) w/v induces ciliary spasm with often migraine intensity brow and/or head aches, and frequently results in increased rebound hyperemia.
  • rebound redness occurs in 25% of patients using brimonidine 0.20%) w/v (Alphagan ® , registered trademark of Allergan, Inc.) twice daily.
  • US Patent Application Publication No. 2014/0113946 describes the use of pilocarpine with the alpha 1 and mild alpha 2 agonist vasoconstrictor oxymetazoline, demonstrating limitations in distance sharpness and duration, whereby a cohort largely restricted to mild hyperopes is required to neutralize the induced myopia (Table 1). Of the 16 eyes treated only three were -0.25 to -0.50 diopters, and eight were mildly hyperopic. Of the -0.50 diopter eyes two were reduced to 20.40 distance. Further, duration was limited as full effect became diminished in about four hours. Pupil size range was from 2.0 mm to 2.7 mm, where enhanced near effect and distance sharpness from depth of focus was minimal to absent.
  • aceclidine are also associated with ciliary spasm, brow and/or headache, and myopic blur.
  • aceclidine is unstable in solution. Normally, aceclidine is stored in a two-bottle system; one bottle containing the lyophilized aceclidine and the second bottle containing the diluent necessary to reconstitute the lyophilized aceclidine before topical instillation.
  • the primary issue with its use as a presbyopic miotic is the attendant pain and in some cases distance blur that may be induced.
  • U.S. Patent No. 9,089,562 describes a composition containing aceclidine combined with a cycloplegic agent, such that in preferred embodiments aceclidine 1.45% is combined with tropicamide 0.042%.
  • aceclidine and the cycloplegic agent require particular narrowly defined ratios and ranges of concentrations relative to each other such that complications in the manufacturing and regulatory process, particularly the need for lyophilization of aceclidine to allow its stable storage, and attendant effects of cryoprecipitant required, where it is a discovery of the present invention the addition of a cryoprecipitate such as a polyol, in a preferred embodiment mannitol, results in reduced efficacy of the defined ranges and ratios of concentrations of US 9,089,562.
  • a cryoprecipitate such as a polyol, in a preferred embodiment mannitol
  • an ophthalmological composition that will allow a person suffering from presbyopia to focus on near objects without significant side effects such as diminished distance vision, blurred vision, pain, redness, impaired night driving or incapacitating dim light vision, induced nasal congestion, or risk of retinal detachment.
  • a cycloplegic agent to be used with aceclidine potentially enhancing duration and efficacy, as well as for means of storage of stable aceclidine compositions, where such compositions preferably enhance both distance and near depth of focus allowing pupil miosis to a 1.50 to 2.0 mm range without clinically significant side effects.
  • the present invention is directed to compositions and methods for the treatment of presbyopia.
  • the present invention is directed to compositions and methods for the treatment of presbyopia comprising a muscarinic agonist, wherein the muscarinic agonist preferentially activates Ml and M3 muscarinic acetylcholine receptors.
  • the muscarinic agonist is more highly selective for Ml than M3.
  • the present invention is directed to compositions and methods for the treatment of presbyopia comprising a muscarinic agonist that preferentially activates Ml and M3 muscarinic acetylcholine receptors.
  • the present invention is directed to compositions and methods for the treatment of presbyopia comprising a muscarinic agonist selected from the group consisting of aceclidine, talsaclidine, sabcomeline, cevimeline, WAY-132983, AFB267B (NGX267), AC-42, AC-260584, 77-LH-28-1, and LY593039 or any pharmaceutically acceptable salts, esters, analogues, prodrugs or derivatives thereof.
  • a muscarinic agonist selected from the group consisting of aceclidine, talsaclidine, sabcomeline, cevimeline, WAY-132983, AFB267B (NGX267), AC-42, AC-260584, 77-LH-28-1, and LY593039 or any pharmaceutically acceptable salts, esters, analogues, prodrugs or derivatives thereof.
  • the present invention is directed to compositions and methods for the treatment of presbyopia comprising a muscarinic agonist that activates only Ml muscarinic acetylcholine receptors.
  • the present invention is directed to an ophthalmological composition for the treatment of presbyopia comprising aceclidine.
  • the present invention is directed to ophthalmological compositions for the treatment of presbyopia comprising aceclidine, preferably at a concentration from about 0.25% to about 2.0% w/v, and a cycloplegic agent at a concentration from about 0.004% to about 0.025% w/v, preferably from about 0.004% to about 0.02% w/v and more preferably the cycloplegic agent is tropicamide.
  • the present invention is directed ophthalmological compositions for the treatment of presbyopia comprising aceclidine, preferably at a concentration from about 0.25% to about 2.0% w/v and a polyol, preferably at a concentration from about 1.0% to about 10.0%) w/v, more preferably mannitol at a concentration from about 2.0% to about 3.0% w/v, wherein the composition is free of a cycloplegic agent.
  • the present invention is directed ophthalmological compositions for the treatment of presbyopia comprising aceclidine, preferably at a concentration from about 0.25% to about 2.0% w/v and a polyol, preferably mannitol at a concentration from about 1.0% to about 10.0% w/v, more preferably 2.5% w/v and from about 0.004% to about 0.025%) of a cycloplegic agent, preferably from about 0.004% to about 0.02% w/v and more preferably the cycloplegic agent is tropicamide.
  • the present invention is directed to
  • ophthalmological compositions for the treatment of presbyopia comprising about 1.65% to about 1.8% aceclidine and about 2.0% to about 3.0% w/v polyol and from about 0.004% to about 0.025%) w/v of a cycloplegic agent, preferably from about 0.004% to about 0.008% w/v and more preferably the cycloplegic agent is tropicamide, preferably at 0.01% w/v.
  • the present invention is directed to ophthalmological compositions for the treatment of presbyopia that further comprise about 1.0% to about 6.0%) w/v nonionic surfactant and/or about 0.1% to about 2.25% w/v viscosity enhancer.
  • the present invention is directed to
  • ophthalmological compositions for the treatment of presbyopia comprising about 1.75% w/v aceclidine, about 2.5% w/v polyol, about 2.75% w/v polysorbate 80, and about 1.80% w/v hydroxypropylmethyl cellulose, and where hydroxypropylmethyl cellulose may in all formulations be substituted for about 1.25% to about 1.45% high molecular weight
  • the present invention is directed to ophthalmological compositions for the treatment of presbyopia comprising about 1.75% w/v aceclidine, about 0.004%> to about 0.007%> w/v tropicamide, about 2.75% w/v polyol, about 2.5% w/v polysorbate 80, and about 1.25% to 1.45% w/v carboxymethyl cellulose, or 1.80% w/v hydroxypropylmethyl cellulose.
  • the present invention is directed to a method of treating presbyopia comprising administering to a subject in need thereof a composition of the present invention.
  • the present invention is directed to a method of treating presbyopia comprising administering to a subject in need thereof an ophthalmological composition of the present invention, wherein near vision acuity of the subject is improved by about 3 lines of resolution or more for at least 6 hours.
  • a method of treating a refractive error of the eye in a subject in need thereof comprising administering to a subject in need thereof a pharmaceutically acceptable amount of a composition of the present invention wherein the refractive error of the eye is selected from presbyopia, myopia, hyperopia, astigmatism or a combination thereof.
  • the present invention is further directed to a method for treating presbyopia comprising administering to a patient in need thereof a composition of the present invention.
  • the present invention is directed to ophthalmological compositions for the treatment of presbyopia comprising:
  • the present invention is directed to ophthalmological compositions for the treatment of presbyopia comprising:
  • the present invention is directed to ophthalmological compositions for the treatment of presbyopia comprising:
  • a nonionic surfactant preferably the nonionic surfactant is selected from a polysorbate, tyloxapol, a poloxamer, a cyclodextrin, vitamin E TPGS and a polyoxyl, more preferably polysorbate 80, even more preferably from about 1.0% to about 5.0%) w/v polysorbate 80 and most preferably from about 2.0% to about 4.0% w/v polysorbate 80; about 0.1%) to about 2.25% w/v hydroxypropylmethyl cellulose, more preferably from about 0.75%) to about 1.5% w/v hydroxypropylmethyl cellulose and most preferably from about 1.0% to about 1.25% w/v hydroxypropylmethyl cellulose; about 0.10%) to about 0.12% w/v sorbic acid;
  • the present invention is directed to ophthalmological compositions for the treatment of presbyopia comprising:
  • w/v mannitol about 1.0% to about 6.0% w/v of a nonionic surfactant, preferably the nonionic surfactant is selected from a polysorbate, tyloxapol, a poloxamer, a cyclodextrin, vitamin E TPGS and a polyoxyl, more preferably polysorbate 80, even more preferably from about 1.0% to about 5.0%) w/v polysorbate 80 and most preferably from about 2.0% to about 4.0% w/v polysorbate 80; about 0.1% to about 2.25% w/v hydroxypropylmethyl cellulose, more preferably from about 0.75%) to about 1.5% w/v hydroxypropylmethyl cellulose and most preferably from about 1.0% to about 1.25% w/v hydroxypropylmethyl cellulose; about 0.10%) to about 0.12% w/v sorbic acid;
  • antioxidants selected from the group consisting of ethylenediaminetetraacetic acid (EDTA), ethylenediaminetetraacetic acid dihydrate, sodium citrate and citrate buffer, preferably selected from the group consisting of ethylenediaminetetraacetic acid dihydrate and sodium citrate or citrate buffer; and
  • the present invention is directed to ophthalmological compositions for the treatment of presbyopia comprising:
  • composition is maintained at a temperature from about 2 to about 8 degrees celsius.
  • the present invention is directed to ophthalmological compositions for the treatment of presbyopia comprising:
  • the present invention is directed to ophthalmological compositions for the treatment of presbyopia comprising:
  • the concentration of hydroxypropylmethyl cellulose is from about 0.1%) to about 2.25% w/v, more preferably from about 0.75% to about 1.5% w/v and most preferably from about 1.0% to about 1.25% w/v.
  • the concentration of hydroxypropylmethyl cellulose is from about 0.1%) to about 2.25% w/v, more preferably from about 0.75% to about 1.5% w/v and most preferably from about 1.0% to about 1.25% w/v.
  • hydroxypropylmethyl cellulose is such that the viscosity is from about 1 to about 10,000 cps prior to instillation, more preferably from about 200 to about 500 cps and most preferably about 400 cps.
  • opththalmological compositions of the present invention comprise one or more antioxidants selected from the group consisting of
  • EDTA ethylenediaminetetraacetic acid
  • sodium citrate and citrate buffer preferably 0.1% w/v ethylenediaminetetraacetic acid dihydrate; and 0.1%) w/v sodium citrate or citrate buffer.
  • the nonionic surfactant is selected from a polysorbate, tyloxapol, a poloxamer, a cyclodextrin, vitamin E TPGS and a polyoxyl, preferably polysorbate 80, more preferably 4.0% w/v polysorbate 80.
  • opththalmological compositions of the present invention have a pH of about 4.0 to about 8.0 for tropicamide free compositions and from about 4.0 to about 6.0 in compositions containing tropicamide and more preferably 5.0 in
  • compositions regardless of tropicamide content.
  • the present invention is directed ophthalmological compositions for the treatment of presbyopia comprising aceclidine, preferably at a concentration from about 0.25% to about 2.0% w/v, a polyol, preferably mannitol at a concentration from about 1.0% to about 10.0% w/v, more preferably 2.5% w/v, and a nonionic surfactant, preferably the nonionic surfactant is selected from the group consisting of a polysorbate, a polyoxyl castor oil, a polyoxyl stearate, a poloxamer, a polyethylene glycol, a polyoxy ethylene glycol alkyl ether, tyloxapol and 2-[[ 10, 13 -dimethyl- 17-(6-methylheptan-2-yl)-2,3 ,4,7, 8,9, 1 1, 12, 14, 15, 16, 17- dodecahydro-lH-cyclopenta[a]phenanthren-3-yl]oxy]
  • the present invention is directed ophthalmological compositions for the treatment of presbyopia comprising aceclidine, preferably at a concentration from about 0.25% to about 2.0% w/v, more preferably 1.75% w/v, a polyol, preferably mannitol at a concentration from about 1.0% to about 10.0% w/v, more preferably 2.5% w/v, tropicamide, preferably at a concentration from about 0.004% to about 0.025% w/v, more preferably about 0.005%) to about 0.007%, a nonionic surfactant, preferably polysorbate 80, more preferably at a concentration of about 0.5% to about 10.0% w/v, more preferably from about 2.0%> to about 6.0% w/v, even more preferably about 2.5% to about 4.0% w/v and a viscosity enhancer, preferably selected from the group consisting of a cellulose derivative, hyaluronate, a carbomer and
  • the present invention is directed ophthalmological compositions for the treatment of presbyopia comprising aceclidine, preferably at a concentration from about 0.25% to about 2.0% w/v, more preferably 1.75% w/v, a polyol, preferably mannitol at a concentration from about 1.0% to about 10.0% w/v, more preferably 2.5% w/v, tropicamide, preferably at a concentration from about 0.004% to about 0.025%> w/v, more preferably about 0.005%) to about 0.007%, a nonionic surfactant, preferably polysorbate 80, more preferably at a concentration of about 0.5% to about 10.0%> w/v, more preferably from about 2.0%> to about 6.0%) w/v, even more preferably about 2.5% to about 4.0% w/v, a viscosity enhancer, preferably selected from the group consisting of a cellulose derivative, hyaluronate, carbomer
  • the present invention is directed to ophthalmological compositions for the treatment of presbyopia comprising aceclidine and tropicamide.
  • the present invention is directed to ophthalmological compositions for the treatment of presbyopia comprising aceclidine at a concentration from about 0.25%) to about 2.0% w/v and a cycloplegic agent.
  • the present invention is directed to ophthalmological compositions for the treatment of presbyopia comprising aceclidine and from about 0.004%) to about 0.08%) w/v of a cycloplegic agent, preferably from about 0.004%> to about 0.049%> w/v and more preferably from about 0.004%) to about 0.025%> w/v.
  • the present invention is directed to ophthalmological compositions for the treatment of presbyopia comprising aceclidine and from about 0.25% to about 2.0%) w/v and from about 0.004%> to about 0.08% w/v of a cycloplegic agent, preferably from about 0.004%) to about 0.049%> w/v and more preferably from about 0.004%) to about 0.025% w/v.
  • the present invention is directed to ophthalmological compositions for the treatment of presbyopia comprising aceclidine and from about 0.25% to about 2.0% w/v and tropicamide at a concentration from about 0.004%> to about 0.08%> w/v, preferably from about 0.004%> to about 0.049%> w/v and more preferably from about 0.004%> to about 0.025% w/v.
  • the present invention is directed to a method of treating presbyopia comprising administering to a subject in need thereof a composition of the present invention.
  • the present invention is directed to a method of treating presbyopia comprising administering to a subject in need thereof an ophthalmological composition of the present invention, wherein near vision acuity of the subject is improved by about 4 lines of resolution or more for at least 8 hours, where it is discovered the addition of a nonionic surfactant at 0.50%> to 10%>, and more preferably 1.0% to 6.0%, and still more preferably at 3.0%> to 5.0%; and optionally one or more of the following: increased viscosity such as in a preferred embodiment about 400 cps using hydroxypropylmethyl cellulose at 1.25%; and addition of a preservative combination of BAK, sorbate and antioxidant combination of one or more of EDTA and citrate; thereby further improve one or more of i) reduced redness; ii) increased lines of near improvement without distance blur; iii) excellent comfort; and iv) enhanced duration.
  • a nonionic surfactant at 0.50%> to 10%>, and more preferably 1.0%
  • the present invention is directed to a method of treating a refractive error of the eye in a subject in need thereof comprising administering to a subject in need thereof a pharmaceutically acceptable amount of a composition of the present invention wherein the refractive error of the eye is selected from presbyopia, myopia, hyperopia, astigmatism or a combination thereof.
  • the present invention is directed to a method of treating a refractive error of the eye comprising administering to a patient in need thereof a
  • a composition of the present invention wherein the size of the pupil is reduced to from about 1.5 to about 2.5 millimeters, preferably from about 1.7 to about 2.2 millimeters and wherein the refractive error is selected from the group consisting of a range of distance corrected vision for mild to moderate hyperopia of 3.0 D or less; mild to moderate myopia of -5.0 D or less; regular astigmatism of 3.0 D or less; uncorrected distance vision for emmetropes of + 0.
  • corneal irregular astigmatism an ectasia induced corneal irregularity, a pellucid induced corneal irregularity, a higher order aberration and a refractive surgery induced higher order aberration.
  • the present invention is further directed to a method of increasing the visual depth of field (i.e. depth of focus) secondary to pupil miosis, comprising administering to a subject in need thereof a pharmaceutically effective amount of an ophthalmological composition of the present invention.
  • the present invention is further directed to a method of reducing the side effects of ophthalmic aceclidine administration by modulating the agonist effect on the ciliary body of the eye such that ciliary spasm, ciliary induced brow ache, and/or ciliary induced headache are substantially reduced or eliminated.
  • the present invention is further directed to a method of allowing binocular physiologic topical presbyopic correction.
  • the present invention is further directed to a method of eliminating the need for monocular limitation due to distance blur, or reduced to treatment of mild hyperopes to counteract induced myopic blur, as typically associated with pilocarpine, or pilocarpine and alpha agonist combinations.
  • the present invention is further directed to a method of improving near vision by increasing accommodation without reduction in distance vision sharpness. This is achieved by simultaneously increasing incremental accommodation, modulated so that while sufficient to provide additive near vision enhancement, it remains at a rate of induction and total degree of accommodation such that the associated myopic blur does not break through the ability of the simultaneously induced pupil miosis pinhole effect to filter the refractive error and maintain distance sharpness.
  • the present invention is further directed to a method of increasing the visual depth perception upon improving near vision unaided comprising administering to a subject in need thereof a pharmaceutically effective amount of an ophthalmological composition of the present invention in both eyes (binocular vision), wherein such binocularity further enhances near vision beyond that of either eye separately.
  • the present invention is further directed to a method of improving vision in a subject with ammetropia (vision abnormality), comprising administering to a subject in need thereof a pharmaceutically effective amount of a composition of the present invention.
  • the present invention is further directed to a method of improving vision in a subject with ammetropia, comprising administering to a subject in need thereof a pharmaceutically effective amount of a composition of the present invention, wherein ammetropia is selected from the group consisting of nearsightedness, farsightedness, regular astigmatism, irregular astigmatism and high degrees of regular astigmatism.
  • the present invention is further directed at eliminating optical aberrations induced by corneal irregularity, opacities, or very high degrees of regular astigmatism that include regions adjacent or peripheral to the central 1.5 mm optical zone, and thereby inducing improved visual acuity and quality of vision by filtering out these aberrant optics in those suffering from irregular astigmatism or high degrees of more regular astigmatism, such as occurs in conditions such as keratoconus, photorefractive keratectomy induced corneal haze, diffuse lamellar keratitis ("DLK”) (post-lasik DLK), other iatrogenic corneal induced irregularity such as cataract incision, glaucoma filtering blebs, implanted glaucoma valves, corneal inlays with or without removal, ectasia post corneal surgery (lasik), and secondary to infection.
  • DLK diffuse lamellar keratitis
  • the present invention is further directed at improving acuity relative to existing uncorrected refractive error.
  • patients now requiring toric contact lenses for astigmatism with reduced comfort and optics that may shift during each blink may in many cases require only non-toric soft contact lenses or no contact lenses. Further, those requiring gas permeable contact lenses may no longer require contact lenses or only require much more comfortable soft contact lenses.
  • Patients with high degrees of astigmatism may now require no correction or reduced astigmatic correction.
  • Patients with small to moderate degrees of nearsightedness may require less correction or no longer require correction.
  • Patients with small to moderate degrees of hyperopia (farsightedness) may require no correction or reduced correction.
  • the present invention is directed to methods and ophthalmological compositions for improving eye sight.
  • the present invention is directed to methods and ophthalmological compositions for the treatment of presbyopia.
  • the present invention is directed to ophthalmological compositions comprising aceclidine.
  • the present invention is directed to methods of treating irregular astigmatism, keratoconic ectasia, and low myopia, or hyperopia, with or without astigmatism, comprising administering to a subject in need thereof an ophthalmological composition of the present invention.
  • the present invention is further directed to a method of stabilizing aceclidine comprising providing a first composition comprising about 1.75% w/v aceclidine and about 2.5% w/v mannitol in a first chamber and a second composition comprising about 0.01% w/v tropicamide, about 4.0%) w/v polysorbate 80, about 1.25% w/v hydroxypropylmethyl cellulose, about 0.10% to 0.12%) w/v sorbic acid, about 0.1%> w/v ethyl enediaminetetraacetic acid dihydrate, about 0.02%) w/v benzalkonium chloride and about 0.1%> w/v sodium citrate or citrate buffer in a second chamber, wherein upon mixing the first composition and the second composition the efficacy of aceclidine is maintained for at least one month.
  • the present invention is further directed to a method of stabilizing aceclidine comprising storing a composition of the present invention at from 0 degrees Celsius to 8 degrees Celsius.
  • the present invention is further directed to a method of inhibiting microbial and fungal growth comprising the following steps:
  • an ophthalmological composition comprising about 1.75% w/v aceclidine, about
  • w/v mannitol about 0.01%> w/v tropicamide, about 4.0% w/v polysorbate 80 and about 1.25%) w/v hydroxypropylmethyl cellulose;
  • Figure 1 is a graphical representation of the effects of pilocarpine and aceclidine with or without tropicamide and with or without a carrier on near and distance vision in a patient over the age of 45.
  • Figure 2 is a graphical representation of the effects of addition of non-ionic surfactants and viscosity enhancers on near vision acuity and duration of effect.
  • Line-Hours denotes lines improved times duration of effect.
  • Figure 3 is a graphical representation of the Efficacy Index for formulas #L33-#L94. Box color denotes a comfort level of good for white, fair for cross-hatched and poor for black. DETAILED DESCRIPTION OF THE INVENTION
  • the present invention is directed to compositions and methods of treating presbyopia, irregular astigmatism, and/or refractive error, comprising administering to a patient in need thereof a pharmaceutical composition comprising a muscarinic agonist that preferentially activates Ml and M3 muscarinic acetylcholine receptors, preferably activate Ml more than M3 and most preferably aceclidine or its derivatives.
  • a pharmaceutical composition comprising a muscarinic agonist that preferentially activates Ml and M3 muscarinic acetylcholine receptors, preferably activate Ml more than M3 and most preferably aceclidine or its derivatives.
  • Aceclidine has been surprisingly and unexpectedly discovered to provide enhanced presbyopic reversal with negligible side effects day or night (when viewing includes one or more direct or reflected light sources) using compositions of the present invention.
  • Aceclidine is traditionally used as a treatment for glaucoma.
  • aceclidine is used to treat glaucoma it is normally stored in a two-bottle system; one bottle containing the lyophilized aceclidine and the second bottle containing the diluent necessary to reconstitute the lyophilized aceclidine before topical instillation.
  • aqueous aceclidine composition that is stable in combination with cold chain storage.
  • It is yet a further aspect of the present invention to provide a method of stabilizing aqueous aceclidine by combining effective excipients, pH ranges and temperature ranges.
  • compositions and methods of the present invention treat presbyopia by improving depth of focus in patients with presbyopia by administering an ophthalmological composition to the eye that reduces pupil dilation in the dark or in dim light, produces a particular degree and duration of miosis without accommodation, provides cosmetic whitening and/or induce redness prophylaxis.
  • the compositions and methods of the present invention also do not cause significant pupil rebound, tachyphylaxis, ciliary spasms, induction of myopia or reduction in distance vision. Additionally, the compositions and methods of the present invention allow for the further improvement in visual acuity and depth perception of binocular (both eyes) treatment.
  • the ophthalmological composition of the present invention surprisingly creates a pupil of from about 1.5 to about 2.4 mm at the anterior iris plane and about 2.0 mm at the corneal surface.
  • the clinical effect appears to involve both with modulated increase in accommodative tone and enhanced pinhole near depth of focus for improved near vision, estimated to be about -1.25 D or less, but restricted in power to remain wihin the range of pinhole correction for distance, found to be about -1.00 D or less creating a sum increase that may in some cases create a near vision add of +2.00 D or more without distance blur; and with a reduction or ablation of the redness that is otherwise a hallmark of the use of miotic agents.
  • accommodative tone is superior to the pinhole effect of the Kamra ® and Flexivue Microlens ® corneal inlays, allowing binocular treatment without peak dimming.
  • Pupil miosis of the present invention with modulated accommodation is also superior to inlays because the constriction of the actual pupil does not result in the attendant severe night vision disturbance caused by the light scattering borders of the pre-corneal pinholes created by the inlays.
  • Further pupil miosis provides a greater field of vision and transmission of more focused light, and in a discovered optimal pupil range of about 1.5 mm to 2.1 mm using formulation discoveries of the present invention does so with negligible to mild and very tolerable dimming and enhanced contrast, distance vision, reduced glare at night, and improved near vision.
  • aceclidine has a minimal effect on the longitudinal ciliary muscle, thus reducing risk of retinal detachment when compared to the use of general muscarinic agonists such as pilocarpine and carbachol.
  • a cycloplegic agent resulted in only 0.04 mm of anterior chamber shallowing.
  • Aceclidine, particularly as enhanced for the present invention also has greater magnitude, duration, and control of minimum pupil diameter than conventional pilocarpine with or without alpha agonists, and less anterior chamber inflammation with chronic use.
  • compositions of the present invention achieve these advantages by allowing both pinhole near vision depth perception benefit and modest accommodative increase below the threshold of induced myopic distance blur through the miotic pupil, whereby, not wishing to be held to particular theory, it is believed the rate of miosis and the rate of accommodative increase maintain a synchronous balance in preferred embodiments allowing pinhole correction of otherwise induced accommodative blur in prior art applications of miotics for presbyopic correction.
  • pilocarpine in order to effect any reasonable duration of effect, are still restricted to less than or equal to about 4 hours in most cases, as the high ratio of accommodation to pupillary miosis requires minimal concentrations of pilocarpine of about 1.0% to minimize but not eliminate distance induced myopic blur and ciliary spasm. Further pilocarpine must be instilled monocularly to minimize intolerable distance blur to a still bothersome 2-3 lines of distance blur. Even instilled monocularly, pilocarpine still may create bothersome attendant distance blur and must be restricted to about 1.0%.
  • pilocarpine pupil size is about 2.3 mm or larger in most subjects and thereby restricts any significant pinhole depth perception benefit as well as any pinhole filtering of induced myopic rays.
  • the restriction to about 1.0% for these conventional formulations of pilocarpine with the attendant short duration and still bothersome but reduced distance blur in emmetropes or myopes (somewhat neutralized in low hyperopes) are attempts to prevent extremely strong
  • any effects on accommodation may be further reduced or totally eliminated in preferred embodiments by combining a miotic with a cycloplegic agent in a narrow and particular ratio of miotic to cycloplegic, where such ratios as discovered for US 9, 089,562, such as about 35: 1 for a preferred embodiment, become greatly increased for the present invention in the presence of cryoprecipitant as to a factor of about 300%> - 700%.
  • Aceclidine is capable of producing the increased depth of focus by both pupil miosis below 2.3 mm and modest accommodation described in the present invention. Particularly enhanced miosis occurs with use of compositions of the present invention.
  • aceclidine may produce either less than optimal pupil miosis at low concentrations or at higher concentrations require more than desired peak miosis to attain satisfactory duration of greater than 3-4 hours.
  • a cycloplegic agent has been found to be highly sensitive to other inactive ingredients in the formulation not usually associated with effects on active agents, and particularly for cryoprecipitants as found to be preferred commercially for aceclidine reduce or eliminate the need for this cycloplegic requirement to extremely low concentrations in a preferred embodiment, rendering 0.042% sufficiently high when
  • cryoprecipitant e.g. a polyol such as mannitol
  • aceclidine without formulation enhancements of the present invention causes dimming of vision in dim or absent lighting as well as ciliary pain above a reasonably tolerable threshold that may last for an hour or more and be similar to a severe migraine headache.
  • Certain embodiments of the present invention enhance the discovered preferred degree of pupillary miosis by providing a consistent range of effect of about 1.50 - 2.20 mm for most patients using a preferred embodiment of a nonionic surfactant and viscosity enhancer. Similar benefit may be achieved using other permeation enhancers, particularly hydroxypropylmethyl cellulose, high viscosity carboxymethyl cellulose, Carbopol ® (polyaciylic acid or carbomer), and various viscosity additives that increase drug residence time, such as xanthan gums, guar gum, alginate, and other in situ gels well known to experts in the art.
  • the present invention further prevents nasal congestion otherwise occurring when substantial aceclidine levels reach the nasal mucosa, due to the rheologic properties of the preferred embodiment.
  • a selective a-2 adrenergic receptor agonist such as fadolmidine, brimonidine or guanfacine
  • a selective a-2 adrenergic receptor agonist such as fadolmidine, brimonidine or guanfacine
  • brimonidine 0.20% w/v when topically applied for pupil modulation for night vision, result in tachyphylaxis of pupil modulation due to a-2 receptor upregulation in almost 100% of treated subjects within four weeks of use.
  • the addition of a cycloplegic agent results in reduction of any brow ache or associated discomfort by further reducing the degree of ciliary spasms on topical instillation without impairing the miotic response.
  • the ratio of 1.40% aceclidine to about 0.040% tropicamide in a preferred embodiment of U.S. Patent No. 9,089,562 (35: 1) becomes about 1.75% aceclidine to about 0.004% to 0.010% tropicamide (350: 1, 175 : 1 respectively) in the presence of mannitol, where 2.5% provides better effect than 4.0%.
  • cycloplegic agents such as tropicamide
  • cycloplegic agents have known pupil dilating effects at concentrations as low as 0.01% w/v (Griinberger J. et al., The pupillary response test as a method to differentiate various types of dementia, Neuropsychiatr, 2009, 23(1), pg 57).
  • More specifically cycloplegic agents cause pupil mydriasis (i.e. dilation of the radial muscle of the iris).
  • the addition of a cycloplegic agent to the miotic agent unexpectedly increases the time at which the pupil maintains the desired size range without becoming too restricted. Peak miotic effect at 30 - 60 minutes can be titrated in inverse relation to the cycloplegic
  • concentrations of tropicamide discovered in the present invention apparently cause more relaxation of the ciliary muscle than the iris radial musculature.
  • iris mydriasis is discovered to be suppressed by the addition of tropicamide to compositions containing concentrations of aceclidine used in the present invention, with instead a more consistent level of miosis for the duration of the miotic effect.
  • the addition of tropicamide can reduce the degree of peak pupil miosis without inducing mydriasis thereby creating a more constant and ideal pupil size throughout the drug induced miosis.
  • This more consistent pupil size allows for beneficial near and distance vision without the adverse dimming or loss of resolution due to diffraction limits at the very reduced pupil sizes seen at peak pupil miosis (e.g. 1.25 mm).
  • aceclidine (1.40%) to the eye, in a preferred embodiment, but such
  • the addition of a polyol can therefore also be used to greatly reduce (i.e. no more than 0.025%> w/v cycloplegic agent, preferably 0.004% to 0.015% and most preferably 0.005% to 0.010%) the concentration of cycloplegic required to further eliminate mild, but potentially bothersome, ciliary side effects particularly in younger presbyopes and further modulate pupil miosis over aceclidine and polyol combinations alone, reducing and in most cases eliminating any bothersome peak concentration dimming, as found in preferred embodiments of the present invention.
  • aceclidine about 1.50% - 2.0% and more preferably 1.75% and mannitol about 0.5% - 4.0% and more preferably 2.5% provide optimal concentration combinations for the present invention, that are necessary but not sufficient for about 3 lines of near improvement and 5 or more hours duration desired for an effective topical presbyopic composition, where additional formulation discoveries can further enhance the desired clinical near improvement magnitude and duration;
  • Viscosity agents such as high viscosity carboxymethyl cellulose ("CMC") are surprisingly discovered to moderately enhance magnitude and greatly enhance duration, unlike with formulations in a. above alone.
  • HPMC hydroxypropylmethyl cellulose
  • citrate in combination with EDTA as a preferred embodiment buffer appears to 1) reduce redness; 2) enhance sorbate preservative shelf life, and in combination of the above with BAK 0.005% to 0.02% (0.02% preferred) further enhances near vision lines to about 4 lines and duration to about 8 to 12 hours.
  • sodium chloride may be substituted with boric acid, preferably at 0.35% or potassium borate, preferably at 0.47%;
  • nonionic surfactant at optimized concentration of about 2.5% to 5.0% enhances permeation of aceclidine into the eye, which may relate to optimal micellar size particularly once of micromicallar or nanomicellar range. This increased permeation coincides with the desirable increase in magnitude and duration and absent tropicamide but in the presence of mannitol with slight increases in ciliary sensation and dimming. Therefore in the presence of the combined formulation enhancements of a-d. above, where a cycloplegic agent is no longer required for a-d.
  • addition of a nonionic surfactant at concentrations found to be preferred may be further improved with much lower concentrations of a cycloplegic agent than those found in US 9.089,562, such as the use of about 0.042% tropicamide with aceclidine 1.40%.
  • a nonionic surfactant at concentrations found to be preferred may be further improved with much lower concentrations of a cycloplegic agent than those found in US 9.089,562, such as the use of about 0.042% tropicamide with aceclidine 1.40%.
  • embodiments include aceclidine of about 1.75%, mannitol 2.5%, polysorbate 80 of about 2.5% to 5.0%, CMC of about 1.42%, or HPMC of about 1.8% and tropicamide of about 0.004% - 0.010%, more preferably about 0.005% to 0.007%, and most preferably about 0.005% - 0.006%.
  • Micelle formation above the critical micellar concentration may allow for micelles to spread across the tear film surface and spread at low concentrations to cover this surface, while at higher concentrations these micelles becoming increasingly contracted and "squeezed" along the surface.
  • a minimal micelle diameter is achieved before significant multiple lamellae (layering) occurs.
  • nanomicelles of about 100 to 250 nm along the surface are achieved surrounding the highly charged and hydrophilic aceclidine, facilitating its penetration through the very lipophilic epithelium;
  • BAK being a cationic surfactant
  • the concentration of such nonionic nucleophiles at a preferred pH in the preferred embodiment is relatively low, but the ability of these nonionic nucleophiles to destabilize adjacent aceclidines repeatedly without themselves degrading is otherwise high.
  • the result may be improved potency for 1 month plus of a mixed solution once opened in a dual chamber bottle and mixing occurs of lyophilized aceclidine/mannitol with the remainder of the formulation in the diluent and or improved stability sufficient for commercialization in solution, either at room temperature or via cold chain;
  • preferred embodiments of the present invention such as containing 1.25% hydroxypropyl methyl cellulose may have a viscosity of about 400 cps prior to instillation, yet unlike conventional high viscosity artificial tear formulations such as Celluvisc® at about 400 cps, which may blur vision for 10-20 minutes or Li qui gel® at about 100 cps, which causes similar but slightly reduced blurring causes only about 60 seconds of blur dissipating rapidly with an influx of tear secretion; where both a
  • nonnewtonian reduction in viscosity at high shear (such as about 1/1000 sec during a blink, and aceclidine parasympathetic trigger of tear secretion as a sialogen may contribute.
  • General miotic agents such as pilocarpine, carbachol and phospholine diesterase, are capable of causing pupil miosis resulting in improved near vision of presbyopic patients.
  • Comfort, safety, and efficacy of a preferred embodiment of an ophthalmological composition of the present invention results from the presence of a nonionic surfactant, such as cyclodextrin alpha, beta, or gamma chains, preferably 2-hydroxypropyl beta-cyclodextrin ("HPpCD"), and, sulfobutyl ether derivative of ⁇ -cyclodextrin (Captisol®), a polyoxyl alkyl such as polyoxyl 40 stearate and polyoxyl 35 castor oil, or a poloxamer such as poloxamer 108 and poloxamer 407, a polysorbate such as polysorbate 80 or Brij® 35(Brij is a registered trademark of Uniqema Americas LLC); a viscosity enhancing agent, such as carboxymethyl cellulose ("CMC”); a tonicity adjustor, such as sodium chloride; a preservative, such as benzalkonium chloride and a pH from
  • an increase in the concentration of the nonionic surfactant may result in reduced redness.
  • increasing polysorbate from 0.10% to 0.50 - 1.0% results in reduced redness.
  • increasing CMC or Carbopol® 940 from 0.50% to 1.5% w/v (preferably 1.40 - 1.43% w/v) results in enhanced near vision, both quantitative improvement and duration improvement.
  • compositions of the present invention comprising a viscosity enhancer may be from about 1 to about 10,000 cps prior to topical instillation in the eye.
  • the viscosity is lowered to a range from about 1 to about 25 cps at the high shear of blinking, and 50 cps to 200 cps at the low shear between blinks, allowing greater drop retention with less spillage and less nasolacrimal drainage and systemic absorption upon topical instillation.
  • composition is intended to encompass a product comprising the specified ingredients in the specified amounts, as well as any product which results, directly or indirectly, from a combination of the specified ingredients in the specified amounts.
  • stabilizing refers to any process which facilitates and/or enables an active agent to remain in solution.
  • stabilizing also refers to any means or process which inhibits and/or reduces the tendency of a muscarinic agonist, including aceclidine, to degrade.
  • % w/v refers to the percent weight of the total composition.
  • the term "subject” refers but is not limited to a person or other animal.
  • muscarinic receptor agonist encompasses agonists that activate muscarinic acetylcholine receptors ("muscarinic receptors"). Muscarinic receptors are divided into five subtypes named M1-M5. Muscarinic agonists of the present invention include those muscarinic agonists that preferentially activate Ml and M3 receptors over M2, M4 and M5 receptors ("M1/M3 agonists").
  • M1/M3 agonists include but are not limited to aceclidine, xanomeline, talsaclidine, sabcomeline, cevimeline, alvameline, arecoline, milameline, SDZ-210- 086, YM-796, RS-86, CDD-0102A (5-[3-ethyl-l,2,4-oxasdiazol-5-yl]-l,4,5,6- tetrahydropyrimidine hydrocholoride), N-arylurea-substituted 3-morpholine arecolines,
  • VUO255-035 N-[3-oxo-3-[4-(4-pyridinyl)-l-piperazinyl]propyl]-2,l,3-benzothiadiazole-4- sulfonamide), benzylquinolone carboxylic acid (BQCA), WAY-132983, AFB267B (NGX267), AC -42, AC -260584, chloropyrazines including but not limited to L-687, 306, L-689-660, 77-LH- 28-1, LY593039, and any quiniclidine ring with one or more carbon substitutions particularly that include an ester, sulfur, or 5 or 6 carbon ring structure including with substituted nitrogen(s) and or oxygen(s), or any pharmaceutically acceptable salts, esters, analogues, prodrugs or derivatives thereof.
  • a preferred M1/M3 agonist is aceclidine.
  • muscarinic agonist of the present invention include those muscarinic agonist that preferentially activate Ml and M3 over M2, M4, and M5; and even more preferably activate Ml over M3.
  • muscarinic agonist of the present invention include those muscarinic agonists that only activate Ml .
  • aceclidine encompasses its salts, esters, analogues, prodrugs and derivatives including, but not limited to, aceclidine as a racemic mixture, aceclidine (+) enantiomer, aceclidine (-) enantiomer, aceclidine analogues, including, but not limited to, highly Ml selective 1,2,5 thiadiazole substituted analogues like those disclosed in Ward. J.S. et al., 1,2,5-Thiadiazole analogues of aceclidine as potent ml muscarinic agonists, J Med Chem, 1998, Jan. 29, 41(3), 379-392 and aceclidine prodrugs including but not limited to carbamate esters.
  • a-2 adrenergic receptor agonists or "a-2 agonist” encompasses all a- 2 adrenergic receptor agonists which have a binding affinity of 900 fold or greater for a-2 over a-1 adrenergic receptors, or 300 fold or greater for a-2a or a-2b over a-1 adrenergic receptors.
  • the term also encompasses pharmaceutically acceptable salts, esters, prodrugs, and other derivatives of selective a-2 adrenergic receptor agonists.
  • low concentrations or "low-dose” of alpha-2 adrenergic receptor agonists refers to concentrations from between about 0.0001% to about 0.065% w/v; more preferably, from about 0.001%> to about 0.035%> w/v; even more preferably, from about 0.01%> to about 0.035%) w/v; and even more preferably, from about 0.03%> to about 0.035%> w/v.
  • brimonidine encompasses, without limitation, brimonidine salts and other derivatives, and specifically includes, but is not limited to, brimonidine tartrate, 5-bromo-6-(2- imidazolin-2-ylamino)quinoxaline D-tartrate, and Alphagan ® .
  • treating and “treatment” refer to reversing, alleviating, inhibiting, or slowing the progress of the disease, disorder, or condition to which such terms apply, or one or more symptoms of such disease, disorder, or condition.
  • pharmaceutically acceptable describes a material that is not biologically or otherwise undesirable (i.e. without causing an unacceptable level of undesirable biological effects or interacting in a deleterious manner).
  • the term "pharmaceutically effective amount” refers to an amount sufficient to effect a desired biological effect, such as a beneficial result, including, without limitation, prevention, diminution, amelioration or elimination of signs or symptoms of a disease or disorder.
  • a desired biological effect such as a beneficial result, including, without limitation, prevention, diminution, amelioration or elimination of signs or symptoms of a disease or disorder.
  • the total amount of each active component of the pharmaceutical composition or method is sufficient to show a meaningful subject benefit.
  • a “pharmaceutically effective amount” will depend upon the context in which it is being administered.
  • a pharmaceutically effective amount may be administered in one or more prophylactic or therapeutic administrations.
  • prodrugs refers to compounds, including, but not limited to, monomers and dimers of the compounds of the invention, which have cleavable groups and become, under physiological conditions, compounds which are pharmaceutically active in vivo.
  • salts refers to those salts which retain the biological effectiveness and properties of the parent compounds and which are not biologically or otherwise harmful at the dosage administered. Salts of the compounds of the present inventions may be prepared from inorganic or organic acids or bases.
  • higher order aberrations refers to aberrations in the visual field selected from starbursts, halos (spherical aberration), double vision, multiple images, smeared vision, coma and trefoil.
  • cold chain refers to storage at temperatures from about 2 to about 8 °C from manufacture to immediately prior to administration.
  • the compounds of the present invention can be used in the form of pharmaceutically acceptable salts derived from inorganic or organic acids or bases.
  • pharmaceutically acceptable salt means those salts which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of humans and lower animals without undue toxicity, irritation, allergic response and the like and are commensurate with a reasonable benefit/risk ratio.
  • Pharmaceutically acceptable salts are well-known in the art. For example, S. M. Berge et al. describe pharmaceutically acceptable salts in detail in J. Pharmaceutical Sciences, 1977, 66: 1 et seq.
  • the salts can be prepared in situ during the final isolation and purification of the compounds of the invention or separately by reacting a free base function with a suitable organic acid.
  • Representative acid addition salts include, but are not limited to acetate, adipate, alginate, citrate, aspartate, benzoate, benzenesulfonate, bisulfate, butyrate, camphorate, camphorsulfonate, digluconate, glycerophosphate, hemisulfate, heptanoate, hexanoate, fumarate, hydrochloride, hydrobromide, hydroiodide, 2-hydroxyethansulfonate (isothionate), lactate, maleate,
  • methanesulfonate nicotinate, 2-naphthalenesulfonate, oxalate, palmitoate, pectinate, persulfate, 3-phenylpropionate, picrate, pivalate, propionate, succinate, tartrate, thiocyanate, phosphate, glutamate, bicarbonate, p-toluenesulfonate and undecanoate.
  • the basic nitrogen-containing groups can be quaternized with such agents as lower alkyl halides such as methyl, ethyl, propyl, and butyl chlorides, bromides and iodides; dialkyl sulfates like dimethyl, diethyl, dibutyl and diamyl sulfates; long chain halides such as decyl, lauryl, myristyl and stearyl chlorides, bromides and iodides; arylalkyl halides like benzyl and phenethyl bromides and others. Water or oil- soluble or dispersible products are thereby obtained.
  • lower alkyl halides such as methyl, ethyl, propyl, and butyl chlorides, bromides and iodides
  • dialkyl sulfates like dimethyl, diethyl, dibutyl and diamyl sulfates
  • long chain halides such as decy
  • acids which can be employed to form pharmaceutically acceptable acid addition salts include such inorganic acids as hydrochloric acid, hydrobromic acid, hyaluronic acid, malic acid, sulphuric acid and phosphoric acid and such organic acids as oxalic acid, malic acid, maleic acid, methanosulfonic acid, succinic acid and citric acid.
  • Basic addition salts can be prepared in situ during the final isolation and purification of compounds of this invention by reacting a carboxylic acid-containing moiety with a suitable base such as the hydroxide, carbonate or bicarbonate of a pharmaceutically acceptable metal cation or with ammonia or an organic primary, secondary or tertiary amine.
  • a suitable base such as the hydroxide, carbonate or bicarbonate of a pharmaceutically acceptable metal cation or with ammonia or an organic primary, secondary or tertiary amine.
  • Pharmaceutically acceptable salts include, but are not limited to, cations based on alkali metals or alkaline earth metals such as lithium, sodium, potassium, calcium, magnesium and aluminum salts and the like and nontoxic quaternary ammonia and amine cations including ammonium, tetramethylammonium, tetraethylammonium, methylammonium, dimethyl ammonium, trimethyl ammonium,
  • Other representative organic amines useful for the formation of base addition salts include ethyl enediamine, ethanolamine, diethanolamine, piperidine, piperazine and the like.
  • esters as used herein is represented by the formula— OC(0)A 1 or— C(0)OA 1 , where A 1 can be alkyl, cycloalkyl, alkenyl, cycloalkenyl, alkynyl, cycloalkynyl, aryl, a heteroaryl group or other suitable substituent.
  • the present invention is directed to an ophthalmological composition
  • an ophthalmological composition comprising aceclidine.
  • aceclidine is at a concentration from about 0.25% to about 2.0% w/v, more preferably from about 0.50% to about 1.90% w/v, still more preferably from about 1.65% to about 1.85% w/v, and most preferably about 1.75% w/v.
  • aceclidine is a tertiary amine with asymmetry, both a + and - optical isomer exist (where in some studies (+) is more potent and in others it is felt (-) may be more potent).
  • polarimetry demonstrated an exactly equal ratio of (+) and (-) isomer for these concentrations. Altering this ratio could therefore alter this concentration range proportional to a change in ratio.
  • the present invention is further directed to an ophthalmological composition
  • a muscarinic agonist preferably a nonionic surfactant above its critical micellar concentration for the composition, and a viscosity enhancing agent; or alternatively an in situ gelling agent.
  • the initial viscosity of the composition on topical application is above 20 cps, preferably 50 cps, and more preferably above 70 cps at low shear (1/s).
  • Nonionic surfactants suitable for the present invention include cyclodextrins, polyoxyl alkyls, poloxamers or combinations thereof, and may include in addition combinations with other nonionic surfactants such as polysorbates.
  • Preferred embodiments include polyoxyl 40 stearate and optionally Poloxamer 108, Poloxamer 188, Poloxamer 407, Polysorbate 20, Polysorbate 80, ionically charged (e.g.
  • beta - cyclodextrins with or without a butyrated salt (Captisol ® ) 2-hydroxypropyl beta cyclodextrin (“HPpCD”), alpha cyclodextrins, gamma cyclodextrins, Polyoxyl 35 castor oil, and Polyoxyl 40 hydrogenated castor oil or combinations thereof.
  • Captisol ® 2-hydroxypropyl beta cyclodextrin
  • HPpCD 2-hydroxypropyl beta cyclodextrin
  • alpha cyclodextrins alpha cyclodextrins
  • gamma cyclodextrins gamma cyclodextrins
  • Polyoxyl 35 castor oil and Polyoxyl 40 hydrogenated castor oil or combinations thereof.
  • nonionizing surfactant such as poloxamer, poloxamer 103, poloxamer 123, and poloxamer 124, poloxamer 407, poloxamer 188, and poloxamer 338, any poloxamer analogue or derivative, polysorbate, polysorbate 20, polysorbate 40, polysorbate 60, polysorbate 80, any polysorbate analogue or derivative, cyclodextrin, hydroxypropyl- ⁇ - cyclodextrin, hydroxypropyl- ⁇ - cyclodextrin, randomly methylated ⁇ -cyclodextrin, ⁇ -cyclodextrin sulfobutyl ether, ⁇ - cyclodextrin sulfobutyl ether or glucosyl- ⁇ - cyclodextrin, any combination of amer analogue or derivative, polysorbate, polysorbate 20, polysorbate 40, polysorbate 60, polysorbate 80, any polysorbate an
  • an anionic surfactant such as sodium lauryl sulfate and or sodium ester lauryl sulfate may be preferred.
  • polysorbate 80 is preferred.
  • any nonionic surfactant is suitable for use in the present invention as long as the concentration of the nonionic surfactant is such that it is above the critical micellar concentration for that non-ionic surfactant.
  • the nonionic surfactants used in the present invention achieve submicron diameter micelles, more preferably less than 200 nanometers and more preferably less than 150 nanometers in diameter.
  • Ophthalmological in situ gels which may be substituted for or added in addition to one or more nonionic surfactants include but are not limited to gelatin, carbomers of various molecular weights including carbomer 934 P and 974 P, xanthan gums, alginic acid (alginate), guar gums, locust bean gum, chitosan, pectins and other gelling agents well known to experts in the art.
  • nonionic surfactant is polyoxyl 40 stearate at a
  • polyoxyl 40 stearate is found to enhance the redness reduction effect preferentially over aqueous solutions and other nonionic surfactants such as poloxamer 407, particularly in the presence of an a-2 agonist.
  • the nonionic surfactant is polysorbate 80 at a
  • concentration from about 0.5% to about 10% w/v, more preferably from about 1% to about 7% w/v and even more preferably from about 2% to about 5% w/v, yet more preferably from about 2.5% to about 4% w/v and most preferably at about 2.5% or 2.75% or 3% or 4% or 5% w/v.
  • Viscosity enhancers suitable for the present invention include, but are not limited to gums such as guar gum, hydroxypropyl-guar ("hp-guar”), and xanthan gum, alginate, chitosan, gelrite, hyauluronic acid, dextran, Carbopol ® (polyacrylic acid or carbomer) including Carbopol ® 900 series including Carbopol® 940 (carbomer 940), Carbopol ® 910 (carbomer 910) and Carbopol ® 934 (carbomer 934), cellulose derivatives such as carboxymethyl cellulose ("CMC"), methylcellulose, methyl cellulose 4000, hydroxymethyl cellulose, hydroxypropyl cellulose, hydroxypropylmethyl cellulose, hydroxyl propyl methyl cellulose 2906, carboxypropylmethyl cellulose, hydroxypropyl ethyl cellulose, and hydroxyethyl cellulose, polyethylene glycol
  • the viscosity enhancer will have an equilibration viscosity less than 100 cps, preferably from about 15 to about 35 cps, and most preferably at about 30 cps.
  • the viscosity enhancer is Carbopol ® 940 (carbomer 940) at a concentration from about 0.05% to about 1.5% w/v, preferably from about 0.09% to about 1.0% w/v, more preferably at 0.09%, 0.25%, 0.5%, 0.75%, 0.9% or 1.0% w/v.
  • nonionic surfactant / viscosity combinations may result in phase separation over time with precipitate formation. In such situations, particularly for polyoxyls, in a preferred embodiment polyoxyl 40 stearate, and cellulose derivatives, particularly
  • the viscosity enhancer is carboxymethyl cellulose at a concentration from about 1% to about 2% w/v, more preferably from 1.35% to about 1.45% w/v and most preferably 1.42% w/v or 1.40%> w/v.
  • the viscosity enhancer is hydroxypropylmethyl cellulose at a concentration from about 0.5% to about 1.75%, and more preferably about 0.75% or 1.5%, still more preferably from about 1.0% to about 1.5%, and most preferably at about 1.25%.
  • Acidic pH preferably less than 5.5, preferably less than 5.0 and most preferably at a pH of about 4.75;
  • Viscosity enhancer preferably at 25C viscosity of about 15-50 cps, and more preferably
  • the selective a-2 agonist may be included within the composition of the present invention or applied topically preferably just minutes before or less preferably just minutes afterward if additional means to reduce nasal congestion or redness is desired for sensitive subjects.
  • Selective a-2 agonists suitable for the present invention have minimal a-1 agonist activity at low concentrations. For example, for brimonidine or fadolmidine, 1% to 2% w/v is considered extremely high, 0.5% to 1.0% w/v still highly inductive of a-1 receptors and toxic for purposes of the present invention.
  • w/v is associated with a higher than preferred incidence of rebound hyperemia (however, for dexmedetomidine, its greater lipophilicity and intraocular penetration reduces rebound risk in this range). Only 0.065% w/v or below is potentially acceptable, where for most a-2 agonists, depending on degree of selectivity 0.050% w/v or even more preferably 0.035% w/v or less is desired. On the other hand some degree of useful activity may occur at one or more orders of magnitude further reduction of concentration.
  • brimonidine, fadolmidine and guanfacine preferentially stimulate a-2 adrenergic receptors, and even more preferably a-2b adrenergic receptors so that a-1 adrenergic receptors are not stimulated sufficiently enough to cause excessive large vessel arteriolar constriction and vasoconstrictive ischemia.
  • preventing or reducing redness for drugs that otherwise directly induce redness such as the acetylcholine agonist, aceclidine, enhances compliance for sensitive subjects that may have induced redness or nasal congestion even with formulations of the present invention that do not include an a-2 agonist.
  • each a-2 agonist has a preferred pH range depending on its lipophilicity and pKa value when added to the inventive compositions with aceclidine.
  • pH range of 5.0 to 8.0 is tolerated, preferred embodiments are at pH 5.5 to 7.5 and more preferably 6.5 to 7.0.
  • cyclodextrins and/or polyoxyl 40 stearate as a nonionic surfactant component or as the sole nonionic surfactant, result in a greater whitening effect when the a-2 agonist is included in the composition rather than poloxamer 407.
  • the a-2 agonist may optionally be applied separately or in certain preferred embodiments with formulations of the present invention that do not include an a-2 agonist, such as those formulas with polyoxyl 40 stearate 5.5% w/v as the non-ionic surfactant, although the a-2 agonist is not required except for occasional sensitive subjects. Fadolmidine represents the a-2 agonist with highest hydrophilicity and therefore high surface retention for the present invention.
  • Guanfacine is also highly selective and hydrophilic.
  • Brimonidine is highly selective with moderate lipophilicity.
  • dexmedetomidine has high selectivity with high lipophilicity that may be used with less efficacy for reducing redness for the purposes of the present invention (although possibly inducing fatigue as a side effect in some patients).
  • w/v results in redness of about 1.0 to 1.5 out of 4 which is transient lasting about ten minutes, and by 30 minutes returns to about baseline.
  • the selective a-2 adrenergic receptor agonist is a compound which has binding affinity of about 900 fold or greater, even more preferably about 1000 fold or greater, and most preferably, about 1500 fold or greater.
  • the selective a-2 adrenergic receptor agonist may be present at a concentration from between about 0.0001%> to about 0.065%> w/v; more preferably, from about 0.001%> to about 0.035%) w/v; even more preferably, from about 0.01%> to about 0.035%> w/v; and even more preferably, from about 0.020% to about 0.035% w/v.
  • the selective a-2 adrenergic receptor is selected from the group consisting of brimonidine, guanfacine, fadolmidine, dexmedetomidine, (+)-(S)-4-[l-(2,3- dimethyl-phenyl)-ethyl]-l,3-dihydro-imidazole-2-thione, l-[(imidazolidin-2-yl)imino]indazole, and mixtures of these compounds. Analogues of these compounds that function as highly selective a-2 agonists may also be used in compositions and methods of the present invention.
  • the selective a-2 agonist is selected from the group consisting of fadolmidine, guanfacine and brimonidine.
  • the selective a-2 agonist is brimonidine in the form of a salt at a concentration of 0.025%> to 0.065%> w/v, more preferably from 0.03%> to 0.035%) w/v.
  • the salt is a tartrate salt.
  • the selective a-2 agonist is fadolmidine at a concentration from about 0.005%) to about 0.05%> w/v, more preferably from 0.02% to about 0.035% w/v in the form of a hydrochloride ("HCl”) salt.
  • HCl hydrochloride
  • the selective a-2 agonist is guanfacine at a concentration from about 0.005%) to about 0.05%> w/v, more preferably from 0.02% to about 0.035% w/v in the form of an HCl salt.
  • the selective a-2 agonist is dexmedetomidine at a concentration from about 0.005%> to about 0.05% w/v, more preferably from 0.04% to about 0.05% w/v in the form of an HCl salt.
  • a pH less than physiologic pH is found to enhance the whitening effect for brimonidine, preferably pH 4.5 to 6.5, and more preferably pH 5.5 to 6.0.
  • redness reduction is achieved at all pHs, and enhancement of aceclidine absorption occurs at alkaline pH, such that more effect occurs from a given concentration, and therefore while effective at pH ranges from 4.5 to 8.0, pH range of 6.5 to 7.5 is preferred for the present invention, and 7.0 to 7.5 most preferred.
  • the present invention is further directed to an ophthalmological composition further comprising a cycloplegic agent.
  • a cycloplegic agent can be combined with miotic agents, particularly for the present invention, aceclidine, without reducing miotic onset, magnitude, or duration; and further blunt the normally attendant spike in miotic effect coinciding with time of peak absorption in aqueous formulations to provide a constant miosis versus time after onset from 15 to 30 minutes to 6 to 10 hours depending on the desired formulation.
  • the addition of the cycloplegic agent also reduces any residual associated discomfort that may otherwise occur soon after topical instillation, which presumably is a result of ciliary spasms or excessive pupillary miosis.
  • Cycloplegic agents suitable for the present invention include, but are not limited to, atropine, Cyclogyl ® (cyclopentolate hydrochloride), hyoscine, pirenzepine, tropicamide, atropine, 4-diphenylacetoxy-N-methylpiperidine methobromide (4-DAMP), AF-DX 384, methoctramine, tripitramine, darifenacin, solifenacin (Vesicare), tolterodine, oxybutynin, ipratropium, oxitropium, tiotropium (Spriva), and otenzepad (a.k.a.
  • the cycloplegic agent is tropicamide at a concentration from about 0.004% to about 0. 025% w/v, more preferably from about 0.005% to about 0.015% w/v and still more preferably from about 0.005% to about 0.011% w/v, from about 0.005%> to about 0.007%) w/v and from about 0.005%) to about 0.006%) w/v.
  • the cycloplegic agent is a mixture of tropicamide at a concentration from about 0.04% to about 0.07%) w/v or pirenzepine or otenzepad at a concentration from about 0.002%) to about 0.05%> w/v.
  • tropicamide 0.01%> w/v was found to slightly reduce brow ache, 0.030%) w/v to further reduce brow ache and from 0.04% to about 0.07% w/v to completely eliminate brow ache without reduction of the average pupillary miosis diameter over duration of effect.
  • Tropicamide in preferred embodiments has demonstrated completely unexpected sensitivity of effect, where at about 0.04% w/v unexpectedly and very effectively reduces or eliminates brow ache and ciliary spasm pain, becoming very noticeably further reduced at 0.042% w/v and absent at 0.044%> w/v in a preferred embodiment with no cycloplegia (surprising due to its common use as a pupil dilating agent).
  • tropicamide did not reduce the mean degree of pupil miosis, the time of onset of pupil miosis or the subsequent visual benefits.
  • tropicamide blunted the peak miosis seen in aqueous formulations to create a smooth consistent miotic effect over time. It allowed modulation of peak pupil miosis to achieve a more even effect over time with no dilation as has been found with its prior use.
  • tropicamide is useful to prevent transient constriction below 1.50 mm at 30 to 60 minutes following aceclidine in some embodiments and to reduce transient excessive and undesirable dimming of vision that may otherwise occur at peak onset of about 30 minutes.
  • an ophthalmological composition comprising 1.53%> w/v aceclidine, 5% w/v ⁇ , 0.75% w/v CMC, 0.25% w/v NaCl , 0.01% w/v BAK and a phosphate buffer at pH 7.0; or 1.45% w/v aceclidine; 5.5% w/v polyoxyl 40 stearate; 0.80% w/v CMC; 0.037% w/v NaCl; 0.015% w/v EDTA; 0.007% w/v BAK and 5mM phosphate buffer at a pH 7.0; was varied from 0.040% w/v tropicamide, where moderate dimming was noted, to 0.044% w/v tropicamide where dimming became almost undetectable other than in extremely dim light conditions.
  • This additional pupil size modulation with a cycloplegic agent allows aceclidine concentrations sufficient for prolonged effect while blunting the attendant peak excessive constriction that is undesirable as well as any uncomfortable brow ache.
  • tropicamide achieves this blunting effect without causing mydriasis.
  • tropicamide 0.014%) w/v was found to reduce brow ache, 0.021% w/v to further reduce brow ache and from 0.028% to 0.060% w/v and in some embodiments up to 0.09% w/v to completely eliminate brow ache without cycloplegia (i.e. paralysis of ciliary muscle of the eye).
  • FIG. 1 shows the effect of a miotic agent with or without a cycloplegic agent and with or without a carrier.
  • Subject is an emmetrope over the age of 45 with a baseline near vision of 20.100 and baseline distance vision of 20.20.
  • Topical administration to the eye of 1% w/v pilocarpine in saline solution results in an improvement of near vision to 20.40 (8a), however this improvement comes at the expense of a reduction in distance vision to 20.100 (8b).
  • the carrier increases the beneficial effect of aceclidine resulting in better than 20.20 near vision.
  • lOe and lOf show the effects of adding 0.042% w/v tropicamide to the aceclidine in the carrier.
  • FIG. 1 shows that aceclidine is capable of temporarily correcting near vision in a presbyopic subject without affecting the baseline distance vision. Similar results can be achieved with a different miotic agent, pilocarpine, with the addition of a cycloplegic agent such as tropicamide. A proper drug carrier can also have a beneficial effect.
  • the present invention is further directed to an ophthalmological composition further comprising a tonicity adjustor and a preservative.
  • a tonicity adjustor can be, without limitation, a salt such as sodium chloride (“NaCl”), potassium chloride, mannitol or glycerin, or another pharmaceutically or ophthalmologically acceptable tonicity adjustor.
  • a salt such as sodium chloride (“NaCl”), potassium chloride, mannitol or glycerin, or another pharmaceutically or ophthalmologically acceptable tonicity adjustor.
  • the tonicity adjustor is 0.037%) w/v NaCl
  • Preservatives that can be used with the present invention include, but are not limited to, benzalkonium chloride ("BAK”), sorbic acid, oxychloro complex, citric acid, chlorobutanol, thimerosal, phenylmercuric acetate, disodium ethylenediaminetetraacetic acid, phenylmercuric nitrate, perborate or benzyl alcohol.
  • the preservative is BAK, sorbic acid, oxychloro complex or a combination thereof.
  • BAK is at a concentration of about 0.001% to about 1.0% w/v, more preferably at a concentration of about 0.007%), 0.01%> or 0.02% w/v.
  • the preservative is perborate at a concentration of 0.01%> to about 1.0% w/v, more preferably at a concentration of about 0.02% w/v.
  • buffers and means for adjusting pH can be used to prepare ophthalmological compositions of the invention.
  • buffers include, but are not limited to, acetate buffers, citrate buffers, phosphate buffers and borate buffers. It is understood that acids or bases can be used to adjust the pH of the composition as needed, preferably of 1 to 10 mM concentration, and more preferably about 3 mM or 5 mM.
  • the pH is from about 4.0 to about 8.0, in a more preferred embodiment the pH is from about 5.0 to about 7.0.
  • the present invention is further directed to an ophthalmological composition further comprising an antioxidant.
  • Antioxidants that can be used with the present invention include but are not limited to disodium ethylenediaminetetraacetic acid at a concentration from about 0.005%) to about 0.50%> w/v, citrate at a concentration from about 0.01%> to about 0.3%> w/w, dicalcium diethylenetriamine pentaacetic acid ("Ca2DTPA”) at a concentration from about 0.001% to about 0.2% w/v, preferably about 0.01% w/v Ca2DTPA which can be formulated by adding 0.0084%> w/v Ca(OH) 2 and 0.0032%> w/v pentetic acid to the formulation and mixing slowly. Further combinations of antioxidants can be used. Other antioxidants that can be used with the present invention include those well known to experts in the art such as
  • ethylenediaminetetraacetic acid at a concentration from about 0.0001%> to about 0.015%> w/v.
  • topical formulations of the present invention particularly one of the preferred embodiments comprising aceclidine 1.35%> to 1.55% w/v; 5.5% w/v polyoxyl 40 stearate; 0.80% w/v CMC; 0.037% w/v NaCl; 0.015% w/v EDTA; 0.007%) w/v BAK; and 5mM phosphate buffer at pH 7.0 result in considerably prolonged contact lens wear and comfort after a single topical instillation daily.
  • the single daily use of the preferred embodiments allowed a subject with dry eye to sleep in his lenses for one week periods where previously even after a single night vision would be blurred and contact lenses coated with film requiring removal and cleaning or replacement (see Example 7).
  • an ophthalmological composition of the present invention comprises aceclidine, a polyol, optionally a cycloplegic agent, a nonionic surfactant at a concentration from about 1% to about 5% w/v and a viscosity enhancer at a concentration of about 0.75% to about 1.6% w/v, preferably about 1.25% to about 1.5% w/v.
  • the ophthalmological composition comprises:
  • mannitol at a concentration of about 2.5% w/v.
  • the ophthalmological composition comprises:
  • aceclidine at a concentration of about 1.75%w/v;
  • the ophthalmological composition comprises:
  • aceclidine at a concentration of about 1.75%w/v;
  • mannitol at a concentration of about 2.5% w/v;
  • polysorbate 80 at a concentration of about 5.0% w/v;
  • carboxymethyl cellulose at a concentration of about 1.4% w/v;
  • pH is about 5.
  • the ophthalmological composition comprises:
  • aceclidine at a concentration of about 1.75%w/v;
  • mannitol at a concentration of about 2.5% w/v;
  • polysorbate 80 at a concentration of about 0.5% w/v;
  • NaCl at a concentration from about 0.10% to about 0.50% w/v;
  • Carbopol® 940 at a concentration of about 0.95% w/v;
  • BAK at a concentration of about 0.01% w/v; and phosphate buffer at a concentration of about 3 mM
  • pH is about 5.
  • the ophthalmological composition comprises: aceclidine at a concentration of about 1.75%w/v;
  • mannitol at a concentration of about 2.5% w/v;
  • polysorbate 80 at a concentration of about 2.0% w/v;
  • Carbopol® 940 at a concentration of about 1.5% w/v;
  • the ophthalmological composition comprises: aceclidine at a concentration of about 1.75%w/v;
  • mannitol at a concentration of about 2.5% w/v;
  • polysorbate 80 at a concentration of about 0.25% w/v;
  • NaCl at a concentration of about 0.1% w/v
  • boric acid at a concentration of about 0.12% w/v;
  • Carbopol® 940 at a concentration of about 0.95% w/v;
  • BAK at a concentration of about 0.015% w/v
  • pH is about 5.
  • the ophthalmological composition comprises: aceclidine at a concentration of about 1.75%w/v;
  • mannitol at a concentration of about 2.5% w/v;
  • polysorbate 80 at a concentration of about 0.50% w/v;
  • boric acid at a concentration of about 0.2% w/v;
  • Carbopol® 940 at a concentration of about 0.95% w/v;
  • BAK at a concentration of about 0.01% w/v
  • pH is about 5.
  • the ophthalmological composition comprises: aceclidine at a concentration of about 1.75%w/v;
  • mannitol at a concentration of about 2.5% w/v;
  • polysorbate 80 at a concentration of about 0.1% w/v;
  • boric acid at a concentration of about 0.2% w/v;
  • Carbopol® 940 at a concentration of about 0.9% w/v;
  • pH is about 5.
  • the ophthalmological composition comprises: aceclidine at a concentration of about 1.75%w/v;
  • mannitol at a concentration of about 2.5% w/v;
  • polysorbate 80 at a concentration of about 0.1% w/v;
  • boric acid at a concentration of about 0.12% w/v;
  • Carbopol® 940 at a concentration of about 0.95% w/v;
  • BAK at a concentration of about 0.01% w/v
  • pH is about 5.
  • the ophthalmological composition comprises: aceclidine at a concentration of about 1.75% w/v;
  • mannitol at a concentration of about 2.5% w/v;
  • polysorbate 80 at a concentration of about 5.0% w/v;
  • pH is about 5.
  • the ophthalmological composition comprises: aceclidine at a concentration of about 1.75%w/v;
  • mannitol at a concentration of about 2.5% w/v
  • polysorbate 80 at a concentration of about 0.25% w/v
  • NaCl at a concentration of about 0.1% w/v
  • boric acid at a concentration of about 0.12% w/v;
  • Carbopol® 940 at a concentration of about 0.95% w/v;
  • BAK at a concentration of about 0.01% w/v.
  • pH is about 5.
  • the ophthalmological composition comprises: aceclidine at a concentration of about 1.75%w/v;
  • mannitol at a concentration of about 2.5% w/v;
  • polysorbate 80 at a concentration of about 0.75% w/v;
  • boric acid at a concentration of about 0.2% w/v;
  • Carbopol® 940 at a concentration of about 0.95% w/v;
  • BAK at a concentration of about 0.01% w/v
  • phosphate buffer at a concentration of about 3 mM.
  • pH is about 5.
  • the ophthalmological composition comprises: aceclidine at a concentration of about 1.75%w/v;
  • mannitol at a concentration of about 2.5% w/v;
  • polysorbate 80 at a concentration of about 0.1% w/v;
  • boric acid at a concentration of about 0.2% w/v;
  • Carbopol® 940 at a concentration of about 0.9% w/v;
  • phosphate buffer at a concentration of about 3 mM.
  • pH is about 5.
  • the ophthalmological composition comprises: aceclidine at a concentration of about 1.75%w/v;
  • mannitol at a concentration of about 2.5% w/v
  • polysorbate 80 at a concentration of about 0.1% w/v
  • NaCl at a concentration of about 0.1% w/v
  • boric acid at a concentration of about 0.12% w/v;
  • Carbopol® 940 at a concentration of about 0.95% w/v;
  • BAK at a concentration of about 0.01% w/v
  • phosphate buffer at a concentration of about 3 mM.
  • pH is about 5.
  • the ophthalmological composition comprises: aceclidine at a concentration of about 1.75% w/v;
  • polyoxyl 40 stearate at a concentration of about 5.0% w/v;
  • mannitol at a concentration of about 2.5% w/v;
  • composition has a pH of about 4.75.
  • the ophthalmological composition comprises: aceclidine at a concentration of about 1.55% w/v;
  • polyoxyl 40 stearate at a concentration of about 5.0% w/v;
  • citric acid monohydrate at a concentration of about 0.1% w/v;
  • mannitol at a concentration of about 4.0% w/v;
  • Carbopol® 940 at a concentration of 0.09% w/v;
  • acetate or phosphate buffer at a concentration of about 3.0 mM
  • composition has a pH of about 5.0.
  • the ophthalmological composition comprises: aceclidine at a concentration of about 1.50% w/v;
  • polyoxyl 40 stearate at a concentration of about 5.5% w/v;
  • mannitol at a concentration of about 2.5% w/v;
  • Carbopol® 940 at a concentration of about 0.85% w/v; and BAK at a concentration of about 0.01% w/v,
  • composition has a pH of about 4.75.
  • the ophthalmological composition comprises:
  • aceclidine at a concentration of about 1.45% w/v;
  • polyoxyl 40 stearate at a concentration of about 5.5% w/v;
  • citric acid monohydrate at a concentration of about 0.1% w/v;
  • Carbopol® 940 at a concentration of about 0.75% w/v
  • composition has a pH of about 4.75.
  • the ophthalmological composition comprises:
  • aceclidine at a concentration of about 1.45% w/v;
  • polyoxyl 40 stearate at a concentration of about 5.5% w/v;
  • mannitol at a concentration of about 2.0% w/v;
  • citric acid monohydrate at a concentration of about 0.1% w/v;
  • Carbopol® 940 at a concentration of about 1.0% w/v,
  • composition has a pH of about 4.75.
  • the ophthalmological composition comprises:
  • the ophthalmological composition comprises:
  • the ophthalmological composition comprises:
  • the ophthalmological composition comprises:
  • the ophthalmological composition comprises:
  • BAK as preservative, with a pH of about 5.0.
  • the ophthalmological composition comprises:
  • the ophthalmological composition comprises:
  • the ophthalmological composition comprises:
  • one or more excipient selected from the group consisting of about 0.50 %> w/v sodium chloride, about 0.02%) w/v benzalkonium chloride, about 0.10% w/v sorbate, about 0.01% w/v
  • EDTA ethylenediaminetetraacetic acid
  • citric acid 0.10% w/v citric acid
  • the ophthalmological composition comprises:
  • pH is about 5.0.
  • the ophthalmological composition comprises:
  • pH is about 5.0.
  • the ophthalmological composition comprises:
  • pH is about 5.0.
  • the ophthalmological composition comprises: aceclidine at a concentration of 1.5% w/v, mannitol at a concentration of 2.5% w/v.
  • the ophthalmological composition comprises:
  • aceclidine at a concentration of 1.55% w/v
  • mannitol at a concentration of 2.5% w/v.
  • the ophthalmological composition comprises:
  • aceclidine at a concentration of 1.6% w/v
  • mannitol at a concentration of 2.5% w/v.
  • the ophthalmological composition comprises:
  • aceclidine at a concentration of 1.65% w/v
  • mannitol at a concentration of 2.5% w/v.
  • the ophthalmological composition comprises:
  • aceclidine at a concentration of 1.7% w/v
  • mannitol at a concentration of 2.5% w/v.
  • the ophthalmological composition comprises:
  • aceclidine at a concentration of 1.75% w/v
  • mannitol at a concentration of 2.5% w/v.
  • the ophthalmological composition comprises:
  • aceclidine at a concentration of 1.80% w/v
  • mannitol at a concentration of 2.75% w/v
  • Carbopol® 940 at a concentration of 0.09% w/v.
  • the ophthalmological composition comprises:
  • aceclidine at a concentration of 1.48% w/v
  • mannitol at a concentration of 1.5% w/v
  • Carbopol® 940 at a concentration of 0.50% w/v.
  • the ophthalmological composition comprises:
  • aceclidine at a concentration of 1.80% w/v
  • mannitol at a concentration of 2.5% w/v
  • Carbopol® 940 at a concentration of 0.9% w/v.
  • Example 1 Effect of aceclidine on vision of subjects aged 47 to 67 years
  • Table 1 demonstrates the effect on the near focus ability of presbyopic subjects before and after ophthalmological administration of a composition containing aceclidine.
  • Each composition included aceclidine in the concentrations indicated and 5.5% w/v HPpCD, 0.75% w/v CMC, 0.25% w/v NaCl and 0.01% w/v BAK.
  • compositions administered to subjects 4 and 5 included 0.125% w/v tropicamide.
  • aceclidine is an enantiomer, the clinical effectiveness may vary with different ratios. For the present studies a nearly exact 50:50 ratio of stereoisomers was measured as best determined by polarimetry. Table 1. Effects of aceclidine on vision of presbyopic patients.
  • Table 2 Effect of concentration of concentration of aceclidine and tropicamide.
  • (C) indicates corrected vision
  • (m) indicates minutes
  • (hr) indicates hour
  • mm indicates millimeters
  • BD indicates baseline distance vision
  • BN indicates baseline near vision
  • BP indicates baseline pupil size
  • OD indicates right eye
  • OS indicates left eye and OU indicates both eyes.
  • Time refers to duration of the effect.
  • aceclidine at a concentration of at least 1.1% w/v was able to reduce the size of the pupil to 1.63 mm 1 hour after topical instillation resulting in corrected near and distance vision for at least 10 hours.
  • Lowering of the concentration of aceclidine to 0.75% w/v (formula #3) reduced the miotic effect to 2.0-2.5 mm after 1 hour and vision correction lasted only 6.5 hours.
  • the addition of 0.03% w/v brimonidine reduced redness of the eye (4 out of 4 without brimonidine, not shown) to 1.5 out of 4 within 30 minutes after topical instillation which was maintained for the entire time vision was corrected.
  • formula #7 To determine the effect of brimonidine on pupil miosis, formula #7, was administered. Administration of formula #7 resulted in only a slight decrease in pupil miosis to 1.70 mm with identical distance and near vision improvement to that of formula #5. A 2-3+ conjunctival injection was noted.
  • Example 3 Effect of concentration of aceclidine, brimonidine, guanfacine, fadolmidine, tropicamide and additives Effect of concentration of aceclidine, brimonidine, guanfacine, fadolmidine, tropicamide and additives.
  • Baseline vision was 20.20 both eyes for distance; 20.70 right eye unaided for near; 20.80 left eye for near (best @ 16").
  • D/C stands for discontinued after eye washing due to intolerable stinging.
  • Aceclidine at a concentration of 1.55% w/v was able to reduce the size of the pupil to about 1.63 mm 30 minutes after topical instillation resulting in corrected near and distance vision to 20.20 or better for at least 6 hours, with noticeable affect lasting about 7.5 hours as seen in Table 3.
  • Lowering of the concentration of aceclidine to 1.25% w/v resulted in useful near vision improvement to about 20.25 - 20.30, but not as effective as at the higher dose range alkaline pH resulted in quicker onset, longer duration, and greater effect.
  • ABUT did not include glycerin, poloxamer 188, or polyoxyl 40 stearate, which resulted in substantial stinging and discontinuation of the experiment with eye flush irrigation immediately after topical instillation.
  • Substitution of guanfacine 0.037%) w/v in AB12T for brimonidine resulted in minimal initial redness with prolonged redness reduction and some degree of whitening, and appeared to provide overall the best cosmesis though requiring slightly higher aceclidine concentration for optimal effect.
  • AB4T and AB6T were repeated both monocularly and binocularly. Substantial improvement in depth perception, near point acuity to 3 pt (20.15), and near point distance (8", 20.20) was noted when both eyes were treated vs. monocular treatment. Monocular treatment resulted in worsening of vision with both eyes open versus testing only the treated eye.
  • Example 4 Effect of concentration of aceclidine, brimonidine, tropicamide, and additives Table 4: Effect of concentration of aceclidine, brimonidine, tropicamide, and additives. #8 #9 #10 #11 #12 #13 #14 #15 #16 #17 #18 #19 #20 #21
  • Ache 0-4 0.25 0.25 0.25 0.25 0.25 0.25 0.25 0.25 0.25 0.25 0.00 0.00 0.00 0.00 0.00 0.25 0.00
  • a decrease in the amount of aceclidine from 1.61% to 1.53% w/v resulted in a pupil size range from 1.8-2.0 mm. Dimming as a result of the restriction of the pupil decreased linearly from 1.5 to 0.5 with the decreased amount of aceclidine. Specifically, the 1.8 to 2.0 mm pupil created 41% more light than the 1.5 to 1.7 mm pupil. Surprisingly, the 1.8 to 2.0 mm pupil had a near depth increase of 1.75 D. This is only a 0.25 D loss from the beneficial 2.00 D seen with the 1.5-1.7 mm range. Thus, the 1.80 to 2.0 mm range produces 41%) more light while still allowing the full benefit of increased near vision in individuals under 60 years of age; whereas, individuals 60 years of age and over still experience total computer benefit and some increased near benefit.
  • Table 4 shows an unexpected result seen in formulas #13 and #17 where the increase of NaCl from 0.25% w/v to a range of 0.50 to 0.75% w/v resulted in an acceptable redness score of only 1.0 even without the addition of the redness reducing agent brimonidine.
  • Formulas #15, #16 and #17 each result in an overall maximum rating of 5 by combining the benefits of: (1) reduced aceclidine concentrations to improve the amount of light produced without significantly affecting the near vision benefits seen in formulas #8 - #12; (2) increased NaCl concentrations resulting in a further reduction in redness even in the absence of brimonidine; and (3) increased CMC concentrations resulting in longer residency time on the eye.
  • Formula #19 is an excellent alternative for the minority of individuals that are high responders to formulas #15- #17 and get noticeable dimming with 1.53% w/v aceclidine.
  • Formula #20 is an excellent alternative for the minority of individuals that are low responders to formula #19.
  • Formula #21 is an excellent alternative for the minority of individuals that are low responders and get poor pupil response with Formula #20.
  • a viscosity enhancer preferably CMC 0.80% w/v or an amount of Carbopol 934 or 940 sufficient to achieve a viscosity of from about 5 to about 35 cps upon topical instillation, such as Carbopol® 940 at a concentration from about 0.09% to about 1.0% w/v;
  • a phosphate, citrate, citrophosphate, or acetate buffer from about 3 to about 10 mM
  • pH is from about 4.75 to about 6.0.
  • Example 7 Use of a preferred embodiment to prolong contact lens wear.
  • a viscosity enhancer preferably CMC 0.80% w/v or an amount of Carbopol 934 or 940 sufficient to achieve a viscosity of from about 5 to about 35 cps upon topical instillation, such as Carbopol® 940 at a concentration from about 0.09% to about 1.0% w/v;
  • a phosphate, citrate, citrophosphate, or acetate buffer from about 3 to about 10 mM
  • pH is from about 4.75 to about 6.0.
  • compositions (Formulas #25 and #26).
  • CAPB cocamidopropyl betaine
  • Replacing polyoxyl 40 stearate with Captisol® (sulfobutylether ⁇ -cyclodextrin) and adding mannitol achieves similar results in redness reduction as the addition of CAPB to polyoxyl 40 stearate but without the attendant ache resulting in the highest overall rating among aceclidine compositions (Formula #32).
  • Captisol® sulfobutylether ⁇ -cyclodextrin
  • aceclidine at a concentration of about 1.40%- 1.80% w/v;
  • polyoxyl 40 stearate at about 5.5% w/v;
  • mannitol at a concentration of about 2.5% to 4.5% w/v;
  • carbomer 940 at a concentration of about 0.09% to about 2.0% w/v;
  • a preservative such as BAK at a concentration of about 0.2% w/v; optionally citrate at a concentration of about 0.1%;
  • acetate or phosphate buffer at 2-100 mM, more preferably 3-5 mM
  • composition has a pH of about 4.50 to about 5.0; and preferably, about 4.75 to about 5.0; and
  • a composition as described above was administered to a 62 year old subject. It resulted in pupils of 1.8-1.9 mm ou, 20.20 + reading vision, and 20.20 + distance vision; whereas without carbomer 940 reduced effectiveness resulted at 2.5% mannitol, and no near vision effect resulted at 4.0% mannitol. No ciliary spasm or loss of distance vision resulted. Onset was within about 15 minutes. Transient redness of about 1+ /out of 4 was noted for about 20 minutes without alpha agonist vasoconstrictor. The presence or absence of BAK had no clinical effect, and was used to provide an optional preservative.
  • aceclidine at a concentration of about 1.50% w/v;
  • polyoxyl 40 stearate at a concentration of about 5.5% w/v;
  • mannitol at a concentration of about 2.5% w/v;
  • citrate at a concentration of about 3 mM
  • composition has a pH of about 4.75.
  • Example 11 Use of compositions containing little or no cycloplegic agent
  • Aceclidine alone causes incidence migraine-like severe ciliary spasm (brow ache) and myopic blur. These effects are inversely correlated to age with subjects age 40 reporting the highest incidence and subject age 60+ reporting the lowest incidence.
  • the addition of a cycloplegic agent reduces ciliary spasms and attendant brow ache, migranious headache, squeezing pressure around eyes or other symptoms of ciliary spasms.
  • the addition of the cycloplegic agent surpri singly, does not reduce the myopic effect of aceclidine.
  • the addition of 2.5% w/v mannitol however does reduce the myopic effect of aceclidine.
  • aceclidine concentration overcomes this reduction in myopic effect seen with the addition of mannitol. Surprisingly, however, the increase in aceclidine is not coincident with an increase in ciliary spasm. Even more surprising, the concentration of the cycloplegic agent can be reduced or even eliminated in the presence of mannitol without an increase in ciliary spasm. Thus, combining a higher concentration of aceclidine with little to no cycloplegic agent in the presence of mannitol results in an improvement of near vision acuity without attendant side effects on par with lower concentrations of aceclidine and higher concentrations of the cycloplegic agent in the absence of a cycloplegic agent.
  • the addition of a nonionic surfactant increases both the quantitative measure of near vision improvement and the duration. This effect is concentration sensitive.
  • the non-ionic surfactant is at least 1%, preferably at least 2%, more preferably from about 1% to about 5%, and most preferably about 5%.
  • polysorbate 80 or polyoxyl 40 stearate at a concentration from about 1% to about 5% w/v results in about 1.5 to about 2.0 lines of improvement and a duration from about 4 to about 5 hours.
  • the increase in concentration of a surfactant may crowd the surface of the cornea, and at an optimal concentration this crowding result in small and probably nanometer diameters, which given the dual polarity of surfactants, where nonionic are most preferred, enhances corneal absorption of the entrapped highly polar aceclidine molecules.
  • a viscosity enhancer in a formulation with optimal ratios of aceclidine, tropicamide and a non-ionic surfactant dramatically improves duration.
  • a formulation of the present invention comprising 1.75% aceclidine, 2.5% mannitol, 0.01% tropicamide, 5% polysorbate 80 improves near vision in a presbyopic patient by up to 3 lines of vision acuity for about 4 to about 5 hours.
  • the addition of 1.4% CMC further increases the near vision improvement to from about 7 to about 10 hours.
  • a threshold above the critical micellar threshold greatly enhances permeation through the cornea by reducing micelle size from micrometers to nanometers. See Figure 2.
  • compositions containing little or no cycloplegic agent are shown in Table 8 below.
  • mm denotes millimeters
  • cm denotes centimeters
  • %* denotes amount can optionally vary from about 0.01% to about 1% w/v.
  • # denotes formulation can include polysorbate 80 or not include polysorbate 80.
  • the efficacy index is demonstrated in Figure 3.
  • the score is calculated by multiplying the lines of improvement in near visual acuity by the number of hours the improvement lasts. For example a score of: 5 is equal to +1 lines of improvement in near visual acuity for 5 hours; 10 is equal to +1.5 lines of improvement for 6.7 hours; 15 is equal to 2 lines of improvement for 7.5 hours; 20 is equal to 2.5 lines of improvement for 8 hours; 25 is equal to 3+ lines of improvement for 8.3 hours and 35 is equal to 3.75+ lines of improvement for 9 hours.
  • formulas containing 1.75% aceclidine and 2.5% mannitol have an increased efficacy and duration in treating presbyopia that is correlated with an increase in polysorbate 80 up to 5.0%) and then inversely correlated with a decrease in CMC from 1.45% to 1.40%
  • This data demonstrates that mannitol can effectively reduce ciliary spasms caused by aceclidine, thus reducing the need for a cycloplegic agent such as tropicamide. Further, this data demonstrates that the addition of a non-ionic surfactant and viscosity enhancer can further enhance the efficacy and duration of compositions containing aceclidine, mannitol and low tropicamide. This data also demonstrates that the use of a cycloplegic agent in aceclidine compositions containing polysorbate 80 and CMC is most beneficial to presbyopic correction when the cycloplegic agent is closer to 0.006% than 0.025%. Finally, this data demonstrates that compositions comprising aceclidine and mannitol are sufficient to correct presbyopia with tolerable pain.
  • Example 14 Use of a preferred embodiment optimizing tropicamide and hydroxypropyl methyl cellulose
  • Comfort, duration and efficacy were assessed. Stinging upon instillation and over the first hour was minimal with a score of 0.25 out of 4. Redness over the first hour was also minimal with a score of 0.5 out of 4 assessed at 20 minutes. Onset of vision improvement occurred with the first 20 to 25 minutes after instillation. Baseline near vision (i.e. 40
  • Table 10 lists the active ingredients, excipients and their concentrations for compositions with both tested and prophetic examples of nonionic surfactants.
  • Comfort and duration for each non-ionic surfactant were also tested and are noted in Table 10. Stinging and Redness are based on a scale of 0 to 4 with 0 being none and 4 being the most severe. Other than Brij® 35 stinging and redness were mild to nearly absent. Duration was excellent for each nonionic surfactant tested.
  • Example 16 Use of a compound containing optimizing nonionic surfactant and antioxidant additives and concentrations
  • HPMC 1.25% w/v high MW equaling viscosity of about 400 cps units
  • Comfort, duration and efficacy were assessed. Stinging upon instillation and over the first hour was minimal for each subject with a score of 0.50 out of 4 for about 15 seconds. Redness over the first hour was also minimal for each subject with a score of 0.25 out of 4 assessed at 20 minutes. Onset of vision improvement occurred with the first 20 to 25 minutes after instillation. For subject 1 baseline near vision (i.e. 40 centimeters) was improved by 4.0 - 4.25 lines of visual acuity and lasted for 11.5 hours. For subject 2 baseline near vision was improved by 3.5 lines of visual acuity and lasted for 9.5 hours. The Efficacy Index score was 47.38 and 33.25, among the highest achieved for any formulation.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Ophthalmology & Optometry (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)

Abstract

L'invention concerne des compositions et des méthodes pour le traitement de la presbytie et d'autres anomalies de la vision. Ces compositions comprennent de préférence de l'acéclidine et un polyol et/ou un agent cycloplégique. Ces compositions contiennent optionnellement un tensioactif, un améliorant de viscosité, un modificateur d'osmolarité et un conservateur.
PCT/US2017/021244 2016-03-17 2017-03-08 Compositions et méthodes de traitement de la presbytie WO2017160548A1 (fr)

Priority Applications (5)

Application Number Priority Date Filing Date Title
CA3017755A CA3017755A1 (fr) 2016-03-17 2017-03-08 Compositions et methodes de traitement de la presbytie
MX2018011300A MX2018011300A (es) 2016-03-17 2017-03-08 Composiciones y metodos para el tratamiento de la presbicia.
EP17767172.4A EP3429584A4 (fr) 2016-03-17 2017-03-08 Compositions et méthodes de traitement de la presbytie
CN201780017733.8A CN108883102A (zh) 2016-03-17 2017-03-08 用于治疗远视眼的组合物和方法
JP2018548865A JP2019508472A (ja) 2016-03-17 2017-03-08 老視の処置のための組成物及び方法

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US15/073,139 US9833441B2 (en) 2013-08-28 2016-03-17 Compositions and methods for the treatment of presbyopia
US15/073,089 US9844537B2 (en) 2013-08-28 2016-03-17 Compositions and methods for the treatment of presbyopia
US15/073,139 2016-03-17
US15/073,089 2016-03-17
US15/235,431 2016-08-12
US15/235,431 US10052313B2 (en) 2013-08-28 2016-08-12 Compositions and methods for the treatment of presbyopia

Publications (1)

Publication Number Publication Date
WO2017160548A1 true WO2017160548A1 (fr) 2017-09-21

Family

ID=59852351

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2017/021244 WO2017160548A1 (fr) 2016-03-17 2017-03-08 Compositions et méthodes de traitement de la presbytie

Country Status (6)

Country Link
EP (1) EP3429584A4 (fr)
JP (1) JP2019508472A (fr)
CN (1) CN108883102A (fr)
CA (1) CA3017755A1 (fr)
MX (1) MX2018011300A (fr)
WO (1) WO2017160548A1 (fr)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019147535A3 (fr) * 2018-01-24 2019-09-12 Eye Therapies, Llc Procédés d'amélioration de la vision
WO2019204401A1 (fr) * 2018-04-19 2019-10-24 Presbyopia Therapies Llc Compositions et procédés pour le traitement de la presbytie
WO2021021644A1 (fr) * 2019-07-26 2021-02-04 Allergan Sales, Llc Compositions et méthodes de traitement de la presbytie
US11077053B2 (en) 2018-08-21 2021-08-03 Allergan, Inc. Alpha-2-adrenergic receptor agonists for treatment of presbyopia, visual glare, visual starbursts, visual halos and night myopia
WO2022094462A1 (fr) * 2020-11-02 2022-05-05 Visus Therapeutics, Inc. Composé de dégradation dans un médicament

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114588156A (zh) * 2022-04-22 2022-06-07 温州医科大学附属眼视光医院 一种眼用制剂及其在治疗老花眼中的应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6120758A (en) * 1998-07-16 2000-09-19 Shaklee Corporation Preservative system for topically applied products
WO2015094392A1 (fr) * 2013-12-18 2015-06-25 Gnt, Llc Compositions et méthodes destinées à traiter le glaucome
US20150290126A1 (en) * 2013-08-28 2015-10-15 Presbyopia Therapies, LLC Compositions and Methods for the Improvement of Distance Vision and the Treatment of Refractive Errors of the Eye

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10052313B2 (en) * 2013-08-28 2018-08-21 Presbyopia Therapies, LLC Compositions and methods for the treatment of presbyopia
US10064818B2 (en) * 2013-08-28 2018-09-04 Presbyopia Therapies, LLC Compositions and methods for the treatment of presbyopia

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6120758A (en) * 1998-07-16 2000-09-19 Shaklee Corporation Preservative system for topically applied products
US20150290126A1 (en) * 2013-08-28 2015-10-15 Presbyopia Therapies, LLC Compositions and Methods for the Improvement of Distance Vision and the Treatment of Refractive Errors of the Eye
WO2015094392A1 (fr) * 2013-12-18 2015-06-25 Gnt, Llc Compositions et méthodes destinées à traiter le glaucome

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of EP3429584A4 *

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019147535A3 (fr) * 2018-01-24 2019-09-12 Eye Therapies, Llc Procédés d'amélioration de la vision
WO2019204401A1 (fr) * 2018-04-19 2019-10-24 Presbyopia Therapies Llc Compositions et procédés pour le traitement de la presbytie
US11077053B2 (en) 2018-08-21 2021-08-03 Allergan, Inc. Alpha-2-adrenergic receptor agonists for treatment of presbyopia, visual glare, visual starbursts, visual halos and night myopia
WO2021021644A1 (fr) * 2019-07-26 2021-02-04 Allergan Sales, Llc Compositions et méthodes de traitement de la presbytie
WO2022094462A1 (fr) * 2020-11-02 2022-05-05 Visus Therapeutics, Inc. Composé de dégradation dans un médicament

Also Published As

Publication number Publication date
JP2019508472A (ja) 2019-03-28
EP3429584A1 (fr) 2019-01-23
CN108883102A (zh) 2018-11-23
EP3429584A4 (fr) 2019-11-13
MX2018011300A (es) 2019-02-18
CA3017755A1 (fr) 2017-09-21

Similar Documents

Publication Publication Date Title
AU2019200623B2 (en) Compositions and methods for the treatment of presbyopia
AU2016280615B2 (en) Storage stable compositions and methods for the treatment of refractive errors of the eye
US9320709B2 (en) Storage stable compositions and methods for the treatment of refractive errors of the eye
US10064818B2 (en) Compositions and methods for the treatment of presbyopia
US9968594B2 (en) Compositions and methods for the treatment of presbyopia
EP3429584A1 (fr) Compositions et méthodes de traitement de la presbytie
US20190038609A1 (en) Compositions and methods for the treatment of presbyopia
WO2020076769A1 (fr) Compositions et procédés pour le traitement de la presbytie
US10052313B2 (en) Compositions and methods for the treatment of presbyopia
US9833441B2 (en) Compositions and methods for the treatment of presbyopia
US20230414494A1 (en) Compositions and methods for the treatment of presbyopia
US10959990B2 (en) Compositions and methods for the treatment of presbyopia
US9844537B2 (en) Compositions and methods for the treatment of presbyopia
US20220233434A1 (en) Compositions and methods for the treatment of presbyopia
US10617763B2 (en) Compositions and methods for the treatment of presbyopia
US20180235946A1 (en) Compositions and methods for the treatment of presbyopia
WO2019204401A1 (fr) Compositions et procédés pour le traitement de la presbytie
US20230398064A1 (en) Compositions and methods for the treatment of presbyopia
US11273150B2 (en) Compositions and methods for the treatment of presbyopia
WO2019135927A1 (fr) Compositions et procédés pour le traitement de la presbytie
WO2016205071A1 (fr) Compositions et méthodes de traitement de la presbytie

Legal Events

Date Code Title Description
ENP Entry into the national phase

Ref document number: 3017755

Country of ref document: CA

ENP Entry into the national phase

Ref document number: 2018548865

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: MX/A/2018/011300

Country of ref document: MX

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2017767172

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2017767172

Country of ref document: EP

Effective date: 20181017

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 17767172

Country of ref document: EP

Kind code of ref document: A1